Abbott Launches Digene Insta on the Go – Instant Relief from Acidity, Anytime, Anywhere
Abbott is redefining on-the-go wellness with the launch of Digene Insta On The Go—a ready-to-use antacid solution that delivers relief in just 2 seconds.
Business Wire India
Abbott is redefining on-the-go wellness with the launch of Digene Insta On The Go—a ready-to-use antacid solution that delivers relief in just 2 seconds. With Digene Insta On The Go, Abbott has introduced a ready-to-use, water-free solution that fits seamlessly into the fast-paced lives of today's consumers. It provides fast and effective relief from acidity, heartburn, and indigestion. 1 Developed for people with busy lifestyles, this fast-acting formula acts in just 2 seconds 2 —delivering convenience. Each 10 ml sachet is ready to use and effectively targets acidity and gas-related discomfort. It is designed for instant use, without the need for water, mixing, or measuring. Simply tear open the sachet and sip for direct relief. Digene Insta On The Go is now available in refreshing mint flavor at Rs.50 for a pack of five single-use sachets. Dr. Jejoe Karankumar, Director of Medical Affairs at Abbott, said, 'Acidity can strike without warning – during a hectic workday, while traveling, or even on your daily commutes 3,4 . This ready-to-use, handy solution delivers rapid relief within seconds and is effective for over two hours 1 . Backed by the trust of a legacy brand, it blends proven efficacy with unmatched convenience—all in a compact, pocket-friendly format designed for life on the move.'
The development of this new format was deeply rooted in consumer insights that revealed a growing demand for fast, discreet, and portable solutions to manage acidity. These insights guided Abbott to reimagine the delivery of relief, resulting in a water-free, single-use sachet that aligns with the spontaneous and mobile nature of modern lifestyles. By listening closely to consumer pain points and preferences, Abbott has created a solution that not only meets but anticipates the needs of today's fast-paced world.
To amplify the launch, Digene has rolled out a high-impact, integrated campaign: 'Acidity Kaheen Bhi Ho, Digene Insta On The Go' . This digital-first initiative spans outdoor activations, retail touchpoints, and online platforms—ensuring visibility where it matters most. The campaign includes engaging films such as the Multiplex Film , the Bus Film , and the Adventure Film . Digene Insta On The Go is a new addition to the Digene range, India's No.1 antacid brand 5 , offering consumers another option for managing acidity. Now available at major pharmacies and online platforms across India, Digene Insta On The Go complements Abbott's trusted range of antacid solutions, including Digene Gel and Tablets.
### Refers to the time taken to bring the pH to 3.5, after the amino acid comes in contact with gastric acid. Improved formula refers to higher strength formula with Higher ANC. An invitro study comparing the Preliminary Antacid Test, Acid Neutralizing Capacity and Acid Neutralizing Potential of two antacid products. URAR. Available at: https://www.ijrar.org/IJRAR24D1385.pdf . Dhawal PP, Barve SS. Preliminary in-vitro evaluation of marketed formulations for antacid activity. Int J Basic Clin Pharmacol. 2019:2319-003. Wisely, R. (2018) Why sleep disorders cause heartburn (and vice versa), Why Sleep Disorders Cause Heartburn (and Vice Versa). Available at: https://www.michiganmedicine.org/health-lab/why-sleep-disorders-cause-heartburn-and-vice-versa Heartburn: Causes, symptoms, and treatment (no date) WebMD. Available at: https://www.webmd.com/heartburn-gerd/understanding-heartburn-basics IQVIA Data April 2025
Disclaimer: The above press release comes to you under an arrangement with Business Wire India. Business Upturn take no editorial responsibility for the same.
Ahmedabad Plane Crash
Business Wire India, established in 2002, India's premier media distribution company ensures guaranteed media coverage through its network of 30+ cities and top news agencies.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Los Angeles Times
3 hours ago
- Los Angeles Times
Opinion: Looking into a lead-filled society
Although the majority of Orange County is filled with clean suburbs where good health and environment is expected, in the city of Santa Ana, there are many industrial regions where the air, water, and soil are polluted. These contaminants create an ugly landscape. More importantly, they pose substantial dangers to residents, who are a historically disproportionately marginalized community. According to the U.S. Environmental Protection Agency (EPA), if the amount of lead in the soil exceeds 400 parts per million (ppm) , it is deemed hazardous to health. The California Office of Environmental Health Hazard Assessment lowered the soil lead risk standard to just 80 ppm . However, in Santa Ana, out of the 1,500 soil samples collected, half of them were found to have exceeded the standard of 80 ppm. Furthermore, some samples were found to have reached an astounding 2,600 ppm, highlighting the severity of the issue. Interestingly, UCI-led research found that in the soil where the median household income was below $50,000, there was a 440% higher amount of lead than in places with a median household income of $100,000. Furthermore, over 50% of unsafe lead found in samples were primarily in places with more minority residents who cannot afford benefits such as health insurance. According to the samples collected, two main causes of the lead contamination issue in Santa Ana were found. The first was the excessive use of lead paint up to the year 1978. Buildings were primarily painted using lead paint, and their paint chips and dust continue to be a risk for lead poisoning. However, the main cause of the lead contamination was found to be from historical gasoline emissions. Santa Ana's many old highways and streets cause higher lead concentrations, especially due to its close proximity to neighborhoods. In fact, high levels of lead in children can cause many neurological issues such as developmental delay, learning difficulties, loss of appetite/weight loss, hearing loss, seizures, and more. Adults can also suffer from high blood pressure, joint/muscle pain, loss of memory and concentration, mood disorders, miscarriage, and other symptoms. Although there are still many challenges that the city of Santa Ana faces in regard to its lead contamination, there are many organizations working to make the city a safer place to live. Recently, an initiative headed by Jovenes Cultivando Cambios, called 'PloNo Santa Ana!' partnered with the Orange County Environmental Justice (OCEJ) organization to launch a General Plan (GP) to test lead, repair the soil, and to provide health care to residents who are impacted by the lead contamination. Furthermore, professors from UCI and community members of the Inequities in Childhood Life-Course Lead Exposure and Academic Neurobehavioral Outcomes (I-CLEAN) work to further study the impact that lead has on children. There are several things that all of us can do to alleviate this problem. For example, you can plant vegetation such as sunflowers, spinach, or corn, which have the ability to remove lead from the soil . Furthermore, such plants add much-needed greenspace to cities like Santa Ana. If you want to help advocate for larger changes, then you can join organizations such as the OCEJ PloNo! movement and help change environmental policies on both local and national levels. All of us can agree that everyone, especially children, deserve to live in clean environments. It is our collective responsibility to ensure that we build a country in which everyone has the right to live free of dangerous pollution and contaminants. Related
Business Upturn
6 hours ago
- Business Upturn
Merck Foundation Together with African and Asian First Ladies Mark ‘World Assisted Reproductive Technology Day' 2025 Through Their ‘More Than a Mother' Campaign
Merck Foundation , the philanthropic arm of Merck KGaA Germany, marks 'World ART (Assisted Reproductive Technology) Day 2025′ together with African and Asian First Ladies, who are also the Ambassadors of 'Merck Foundation More Than a Mother' Campaign, by building and advancing fertility care capacity in Africa and Asia. Business Wire India Merck Foundation has made history by training the first local Embryologists and Reproductive & Fertility Experts in many countries such as The Gambia, Liberia, Burundi, Guinea, Chad, Niger, Sierra Leone, Malawi, and Congo. Moreover, supported training for the staff of First Public IVF Centers in Rwanda, Burundi, Ethiopia, Niger, Bangladesh, and Myanmar. Merck Foundation launched 'More Than a Mother Animation Film' that raises awareness about breaking infertility stigma, infertility prevention and male infertility, watch here: Merck Foundation , the philanthropic arm of Merck KGaA Germany, marks 'World ART (Assisted Reproductive Technology) Day 2025′ together with African and Asian First Ladies, who are also the Ambassadors of 'Merck Foundation More Than a Mother' Campaign, by building and advancing fertility care capacity in Africa and Asia. Senator, Dr. Rasha Kelej, CEO of Merck Foundation and President of 'More Than a Mother' emphasized, "At Merck Foundation we mark World Assisted Reproductive Technology Day by building Fertility and Reproductive Care capacity and empowering infertile women by improving their access to information, change of mindset and quality & equitable fertility care across Africa & Asia as part of our 'More than a Mother' campaign. I am very proud to share that we have provided till today 716 scholarships of Embryology, Fertility and Sexual & Reproductive care to young doctors from 41 countries in Africa and Asia to be the local Embryologists, Fertility & Reproductive care experts in their countries. Moreover, many of our Alumni were trained to be the first local experts in their countries where they never had even a single local embryologist or fertility specialist before our program such as; The Gambia, Burundi, Guinea, Chad, Niger, Sierra Leone, Liberia, Malawi, Congo, Mozambique and more. Together with African First Ladies, and other important partners, we are making history and reshaping the landscape of fertility & Reproductive care across Africa and beyond,' added Dr. Kelej. Merck Foundation 'More Than a Mother' is a powerful campaign that defines interventions to build quality and equitable Reproductive and Fertility Care Capacity, Break Infertility Stigma and Raise Awareness about Infertility Prevention and Male Infertility. Merck Foundation has provided 2280 scholarships for doctors from 52 countries in 44 critical and underserved medical specialties. 'To give an overview, out of our total 716 scholarships for Fertility and Reproductive care, we have provided more than 324 Scholarships for clinical and practical training to Fertility Specialists and Embryologists, and more than 392 Scholarships for PG Diploma and Master Degree in Sexual and Reproductive Medicine, Clinical Psychiatry, Women's Health, Biotechnology of Human Assisted Reproduction & Embryology, Urology, Laparoscopic Surgical skills and Family Medicine to doctors from 41 countries across Africa and Asia. We are proud of this achievement,' added Dr. Rasha Kelej. According to WHO data, more than 180 million couples in developing countries – that is 1 in every 4 couple, suffer from infertility. In many cultures in Africa, infertility is a huge stigma. Women are solely blamed for failing to conceive and the social stigma of childlessness, especially for women leads to isolation and stigmatization and results in discrimination and ostracism. This mostly also leads to divorce or physical or psychological violence. As a part of 'More Than a Mother' Campaign, Merck Foundation has launched many initiatives to break this stigma and create a culture shift. Merck Foundation has also been empowering childless and infertile women through their 'Empowering Berna' initiative under their 'More Than a Mother' movement. This initiative helps women who cannot be treated for infertility anymore by helping them get trained to establish small businesses so that they can be independent and rebuild their lives. Through 'Empowering Berna', the lives of many infertile women have been transformed in many African countries like Kenya, Uganda, Nigeria, Central African Republic, Niger, Malawi, and many more. 'It's all about giving every woman the respect and the help she deserves to lead a fulfilling life, with or without a child,' added Dr. Kelej. Moreover, Merck Foundation has trained more than 3700 media representatives from more than 35 countries to raise community awareness and break the stigma around infertility and infertile and childless women. Merck Foundation in partnership with Africa's First Ladies, has also launched 'More Than Mother' Children's storybook to emphasize strong family values of love and respect from a young age which will reflect on eliminating the stigma of infertility and the resulted domestic violence in the future. The storybooks have been localized for each country and in three languages, English, French and Portuguese to better connect with the young readers. The book has also been adapted to an animation film. Watch More Than a Mother Animation Film here: Merck Foundation's pan African TV program 'Our Africa', that is conceptualized, produced, directed, and co-hosted by Senator, Dr. Rasha Kelej, CEO of Merck Foundation and features African Fashion Designers, Singers, and prominent experts from various domains with the aim to raise awareness and create a culture shift across Africa, has many episodes dedicated to raise awareness about infertility and breaking infertility stigma. Watch the episodes here: Episode 3: Episode 5: Episode 10: Merck Foundation has also released about 30 songs, many of these songs have been created with the aim to break the infertility stigma, as a part of their 'More Than a Mother' campaign. Listen to some of the songs here: Watch, share & subscribe to the 'Plus qu'une MERE' composed and sung by Ms. Lucky-Lou, the daughter of The President and The First Lady of Burundi: Watch, share & subscribe to the 'More Than a Mother' song by Cwesi Oteng and Adina from Ghana: Watch, share & subscribe to the 'More Than a Mother' song by Zambian Soul Singer Wezi: Watch, share & subscribe to the 'More Than a Mother' song by Sunita Daffeh from the Gambia: Listen to all 'More than a Mother' songs here: 'To address this important issue of breaking infertility stigma and also a wide range of other social issues, we annually launch Merck Foundation 'More Than a Mother' Awards in partnership with African First Ladies. I would also like to invite the African Community of Media, Fashion, Filmmaking, and Musicians, students, and potential talents in these fields to apply for the awards this year by sharing their creative work on [email protected] , ' concluded Senator, Dr. Rasha Kelej. Click on the link below to Download Merck Foundation App Join the conversation on our social media platforms below and let your voice be heard! Facebook: Merck Foundation X: @MerckFoundation YouTube: MerckFoundation Instagram: Merck Foundation Threads: Merck Foundation Flickr: Merck Foundation Website:
Business Upturn
a day ago
- Business Upturn
LEO Pharma Announces FDA Approval of ANZUPGO® (delgocitinib) Cream in the U.S.
By Business Wire India Published on July 24, 2025, 21:59 IST Business Wire India ANZUPGO® (delgocitinib) cream now becomes the first and only FDA-approved treatment specifically approved for the treatment of adults living with moderate-to-severe chronic hand eczema (CHE) in the U.S. 1 CHE affects approximately one in ten adults worldwide, yet previously, there has been no specific treatment FDA-approved for those living with the disease. 2,3 The approval represents an important milestone for LEO Pharma's expanding presence in the U.S. as it broadens its portfolio of dermatology treatments to address unmet needs. LEO Pharma, a global leader in medical dermatology, announced today that the U.S. Food and Drug Administration (FDA) has approved ANZUPGO® (delgocitinib) cream (20 mg/g) for the topical treatment of moderate-to-severe chronic hand eczema (CHE) in adults who have had an inadequate response to, or for whom topical corticosteroids are not advisable.1 ANZUPGO is an innovative steroid-free, topical pan-Janus kinase (JAK) inhibitor for adults with CHE.1 ANZUPGO inhibits the JAK-STAT pathway, specifically blocking the activity of JAK1, JAK2, JAK3, and tyrosine kinase 2 (TYK2), and suppresses the various inflammatory responses that play a key role in the onset and subsequent flares of CHE.1,2,4 The FDA approval of ANZUPGO marks a significant milestone in LEO Pharma's strategy to expand its presence in the U.S. market and deliver purposeful innovation in skin health. In preparation for bringing ANZUPGO to the U.S. patients, LEO Pharma has significantly upscaled its operations across key functions – including a 50% increase in the sales force. 'ANZUPGOis a good example of how we transform a real need in the market into medicines that can help make a difference for people living with serious skin diseases such as CHE,' said Christophe Bourdon, CEO, LEO Pharma. 'After successfully launching ANZUPGOin several countries, we're proud to now bring this innovation to adult patients with moderate-to-severe CHE in the United States. The approval of ANZUPGO reinforces our commitment to investing in difficult-to-treat skin conditions to deliver new treatments to patients where the need is greatest. We're truly grateful to the patients and physicians who participated in our studies and helped make this approval possible.' CHE is a highly debilitating inflammatory skin disease that affects approximately one in ten adults worldwide, causing itchy, painful, blistered, or swollen skin that can interfere with daily activities.2,3,5,6 The FDA approval of ANZUPGO provides adults in the U.S. living with moderate-to-severe CHE with the first and only treatment option specifically approved for this skin disease, just as it will be the first and only topical pan-JAK-inhibitor on the U.S. market. 'Chronic hand eczema can be a very difficult disease for adults to manage, especially given the lack of treatment options in the U.S. until now,' said Robert Spurr, EVP and President, North America, LEO Pharma. 'As the first and only FDA-approved treatment specifically for CHE in the U.S., ANZUPGO further establishes our company's real commitment to bringing treatments to market that address unmet needs in medical dermatology.' The FDA approval is the latest regulatory milestone for ANZUPGO, following the European Commission (EC) approval in 2024 and several launches internationally, including Germany, Switzerland, the United Kingdom and the United Arab Emirates. *Ends* About ANZUPGO®(delgocitinib) Cream ANZUPGO® (delgocitinib) cream is currently FDA approved in the U.S. as the first and only treatment for chronic hand eczema (CHE). ANZUPGO is also approved in the European Union, United Kingdom, Switzerland and the United Arab Emirates for the treatment of moderate-to-severe chronic hand eczema (CHE) in adults for whom topical corticosteroids are inadequate or not advisable. ANZUPGO cream is also under investigation in other markets. Use of ANZUPGO in combination with other JAK inhibitors or potent immunosuppressants is not recommended by the U.S. FDA.1 ANZUPGO cream is a topical pan-Janus kinase (JAK) inhibitor for the treatment of moderate-to-severe CHE in adults. It inhibits the activation of JAK-STAT signaling, which plays a key role in the pathogenesis of CHE.7 In 2014, LEO Pharma A/S and Japan Tobacco Inc. (JT) entered into a license agreement in which LEO Pharma gained exclusive rights to develop and commercialize delgocitinib for topical use in dermatological indications worldwide, excluding Japan, where JT retains rights. The full U.S. FDA Prescribing Information and Medication Guide are available here: About Chronic Hand Eczema Chronic hand eczema (CHE) is defined as hand eczema (HE) that lasts for three or more months or relapses twice or more within a year.5,8 HE is one of the most common skin disorders of the hands and in a substantial number of patients, it can develop into a chronic condition.9 CHE affects approximately one in ten adults worldwide.2,3 It is a fluctuating disorder characterized by itch and pain, and patients may experience signs such as erythema, scaling, lichenification, hyperkeratosis, vesicles, edema, and fissures on hands and wrists.6 The pathophysiology is characterized by skin barrier dysfunction, inflammation of the skin, and alterations of the skin microbiome.2 CHE has been shown to cause psychological and functional burdens that impact patient quality of life,10,11 with approximately 70% of individuals who live with severe CHE admitting to problems in performing everyday activities.12 Furthermore, careers and earning potential have also been shown to be impacted by the burden of living with CHE.13 About LEO Pharma LEO Pharma is a global leader in medical dermatology. We deliver innovative solutions for skin health, building on a century of experience with breakthrough medicines in healthcare. We are committed to making a fundamental difference in people's lives, and our broad portfolio of treatments serves close to 100 million patients in over 70 countries annually. Headquartered in Denmark, LEO Pharma has a team of 4,000 people worldwide. LEO Pharma is co-owned by majority shareholder the LEO Foundation and, since 2021, Nordic Capital. For more information, visit References ANZUPGO® (delgocitinib) cream. Prescribing Information. FDA. July 2025. Lee GR, Maarouf M, Hendricks AK, Lee DE, Shi VY. Current and emerging therapies for hand eczema. Dermatol Ther. 2019;32(3):e12840. Quaade AS, Simonsen AB, Halling A-S, Thyssen JP, Johansen JD. Prevalence, incidence, and severity of hand eczema in the general population – A systematic review and meta-analysis. Contact Dermatitis. 2021;84:361–374. Tanimoto A, Ogawa Y, Oki C, Kimoto Y, Nozawa K, Amano W, Noji S, Shiozaki M, Matsuo A, Shinozaki Y, Matsushita M. Pharmacological properties of JTE-052: a novel potent JAK inhibitor that suppresses various inflammatory responses in vitro and in vivo. Inflamm Res. 2015;64:41-51. Lynde C, Guenther L, Diepgen TL, et al. Canadian hand dermatitis management guidelines. J Cutan Med Surg. 2010;14(6):267-284. Erratum in: J Cutan Med Surg. 2011 Nov-Dec;15(6):360. Thyssen JP, Schuttelaar MLA, Alfonso JH, et al. Guidelines for diagnosis, prevention, and treatment of hand eczema. Contact Dermatitis. 2022;86(5):357-378. Dubin C, Del Duca E, Guttman-Yassky E. Drugs for the Treatment of Chronic Hand Eczema: Successes and Key Challenges. Ther Clin Risk Manag. 2020;16:1319-1332. Erratum in: Ther Clin Risk Manag. 2021 Mar 18;17:233. Diepgen TL, Andersen KE, Chosidow O, et al. Guidelines for diagnosis, prevention and treatment of hand eczema. J Dtsch Dermatol Ges. 2015;13(1):e1-e22. Bissonnette R, Diepgen TL, Elsner P, et al. Redefining treatment options in chronic hand eczema (CHE). J Eur Acad Dermatol Venereol. 2010;24 Suppl 3:1-20. Grant L, Seiding Larsen L, Burrows K, et al. Development of a Conceptual Model of Chronic Hand Eczema (CHE) Based on Qualitative Interviews with Patients and Expert Dermatologists. Adv Ther. 2020;37(2):692-706. Dalgard FJ, Gieler U, Tomas-Aragones L, et al. The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries. J Invest Dermatol. 2015;135(4):984-991. Cortesi PA, Scalone L, Belisari A, et al. Cost and quality of life in patients with severe chronic hand eczema refractory to standard therapy with topical potent corticosteroids. Contact Dermatitis. 2014;70(3):158-168. Voorberg AN, Loman L, Schuttelaar MLA. Prevalence and Severity of Hand Eczema in the Dutch General Population: A Cross-sectional, Questionnaire Study within the Lifelines Cohort Study. Acta Derm Venereol. 2022;102:adv00626. MAT-84121 July 2025 View source version on Disclaimer: The above press release comes to you under an arrangement with Business Wire India. Business Upturn take no editorial responsibility for the same. Ahmedabad Plane Crash Business Wire India, established in 2002, India's premier media distribution company ensures guaranteed media coverage through its network of 30+ cities and top news agencies.
